Literature DB >> 17105597

Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C.

Cláudia Alves Couto1, Luciana Costa Faria, Daniel Dias Ribeiro, Kátia de Paula Farah, Osvaldo Flávio de Melo Couto, Teresa Cristina de Abreu Ferrari.   

Abstract

BACKGROUND: Interferon-alpha (IFN-alpha)and ribavirin combination therapy for chronic infection with hepatitis C virus produces a number of well-described side effects. Combination therapy with pegylated interferon (PEG-IFN) yields an adverse event profile similar to that observed with the standard IFN, although the frequency of certain adverse events may vary according to the preparation. CASE REPORT: We report the case of a 44-year-old man who was treated with ribavirin and PEG-IFN-alpha-2b for chronic hepatitis C and developed two rare side effects simultaneously on the 16th week of therapy: severe thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis. The antiviral treatment was immediately interrupted and the patient received immunosuppressive therapy. He promptly recovered from the thrombocytopenia and partially and slowly from the nephrotic syndrome. To our knowledge, this is the first case reported of the development of such complications at the same time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17105597     DOI: 10.1111/j.1478-3231.2006.01361.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

1.  Nephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C.

Authors:  Ajit Sood; Vandana Midha; Jaswinder S Sandhu; Neena Sood; Amarjit Kaur; Rasham Mittal; Sandeep Puri
Journal:  Indian J Gastroenterol       Date:  2010-06

2.  Interferon-alpha induced severe thrombocytopenia: a case report and review of the literature.

Authors:  Li Li; Da-Kang Han; Jun Lu
Journal:  World J Gastroenterol       Date:  2010-03-21       Impact factor: 5.742

3.  Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome.

Authors:  Mehmet Enes Coskun; Sue Height; Anil Dhawan; Nedim Hadzic
Journal:  BMJ Case Rep       Date:  2017-07-14

4.  Severe immune thrombocytopenia after peg-interferon-alpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature.

Authors:  Rosario Arena; Paolo Cecinato; Andrea Lisotti; Federica Buonfiglioli; Claudio Calvanese; Giuseppe Grande; Marco Montagnani; Francesco Azzaroli; Giuseppe Mazzella
Journal:  World J Hepatol       Date:  2015-06-28

5.  Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis.

Authors:  Glen S Markowitz; Samih H Nasr; M Barry Stokes; Vivette D D'Agati
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 8.237

Review 6.  De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).

Authors:  Fabrizio Fabrizi; Alessio Aghemo; Gabriella Moroni; Patrizia Passerini; Roberta D'Ambrosio; Paul Martin; Piergiorgio Messa
Journal:  Dig Dis Sci       Date:  2013-12-08       Impact factor: 3.487

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.